Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis-Reference-Cited by-同舟云学术

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis

Published:2024-04 Issue:4 Volume:25 Page:455-462
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Goulart Bernardo Haddock Lobo,Mushti Sirisha L,Chatterjee Somak,Larkins Erin,Mishra-Kalyani Pallavi S,Pazdur Richard,Kluetz Paul G,Singh Harpreet

Funder

U.S. Food and Drug Administration

Publisher

Elsevier BV

Reference24 articles.

1. Endpoints for assessing drug activity in clinical trials;Pazdur;Oncologist,2008

2. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for Industry;US Food and Drug Administration,2018

3. Food and Drug Administration approvals in phase 3 cancer clinical trials;Abi Jaoude;BMC Cancer,2021

4. U.S. FDA drug approvals for breast cancer: a decade in review;Arora;Clin Cancer Res,2022

5. Strategies and end points in the development of novel immunotherapy trials for patients with unresectable, locally advanced non-small-cell lung cancer;Pennell;J Clin Oncol,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB);2024-09-11

2. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

3. Identification and validation of GIMAP family genes as immune-related prognostic biomarkers in lung adenocarcinoma;Heliyon;2024-06

4. PD-L1 as a predictive factor for non-small-cell lung cancer prognosis;The Lancet Oncology;2024-06

5. Pragmaticism in Cancer Clinical Trials;American Society of Clinical Oncology Educational Book;2024-06